ImmuMab - 大分子药物发现 - 服务解决方案

Ailux

MILESTONE: Ailux enters into an AI licensing agreement with UCB for biologics discovery

Contact us

Illuminating Biologics with AI

Delivering transformative biologics

Ailux is an AI-driven drug discovery platform committed to developing highly differentiated biologics with a pragmatic mindset. Our innovative approaches are designed to tackle real-world bottlenecks in drug discovery, enabling the design of better biologics faster and smarter.

Learn more about us

End-to-end AI-driven platform

Our platform delivers unique value from comprehensive hit generation to next-generation lead optimization, unlocking engineering possibilities and maximizing therapeutic differentiation.

Intelligence co-evolution

At the core of our platform is a suite of industry-leading foundational AI models, built upon a proprietary biologics database. Guided by emerging therapeutic concepts and disease biology, we continuously advance our AI-driven approaches to address complex biologics design challenges—from conditionally activated antibodies to multispecific T-cell engagers.

Data leadership

We curate a comprehensive, multi-modal biologics database using advanced techniques such as single B-cell sequencing. By intentionally incorporating both positive data and negative outcomes—such as molecules with poor developability—we create a robust foundation for training large-scale generative and predictive models with greater accuracy and relevance.

Real-world application

Trusted by industry partners, we deliver tailored, differentiated solutions to drug discovery challenges once considered intractable. Our comprehensive hit panels are readily engineerable for advanced attributes, opening the door to novel therapeutic opportunities and addressing unmet medical needs.

Discover our platform

Transforming patient care with better biologics

Our pipeline focuses on cutting-edge antibody-based therapeutics in oncology and immunology, aiming to deliver best-in-class potential through multi-pronged differentiation. Our unique platform-driven approach enables rapid validation of high-value therapeutic hypotheses by delivering safe and effective clinic-ready candidates.

At the core of our pursuit of best-in-class medicines is a strong emphasis on differentiated biological and pharmacological mechanisms that address critical unmet patient needs. Our end-to-end platform is recognized for solving the most challenging molecular design problems at scale, providing a validated path to deliver novel disease-modifying mechanisms for difficult-to-treat conditions.

Explore our biologics

Our pipeline focuses on cutting-edge antibody-based therapeutics in oncology and immunology, aiming to deliver best-in-class potential through multi-pronged differentiation. Our unique platform-driven approach enables rapid validation of high-value therapeutic hypotheses by delivering safe and effective clinic-ready candidates.

At the core of our pursuit of best-in-class medicines is a strong emphasis on differentiated biological and pharmacological mechanisms that address critical unmet patient needs. Our end-to-end platform is recognized for solving the most challenging molecular design problems at scale, providing a validated path to deliver novel disease-modifying mechanisms for difficult-to-treat conditions.

Explore our biologics

Innovate together to build transformative medicines.

Collaborate with us

UCB partners with Ailux Biologics, aDivision of XtalPi, on Biologics AlPlatform

January 9, 2025

Ailux Biologics, a Division of XtalPi, Enters into a License Agreement with Janssen Biotech on Biologics AI Platform

December 20, 2024

Offcial Press Release: IntroducingAilux Biologics by XtalPi